Liraglutide was also associated with a decrease in death from cardiovascular causes and death from any cause, and did not increase the risk of hospitalization due to HF in the overall patient population
Eur J Prev Cardiol 25:495502 Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE (2015) Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes
However, its important to remember that individual responses vary
Faster absorption can lead to quicker onset of appetite suppression but may also intensify nausea during the first few hours after injection
We examine the benefits of IV treatments to recovering from illness